戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 causes including antiplatelet agents and the new oral anticoagulants.
2                                              New oral anticoagulant agents are effective and safe alt
3 Further clinical research is required before new oral anticoagulant agents can be considered standard
4 suspected PE, and the efficacy and safety of new oral anticoagulant agents in patients with cancer.
5                                              New oral anticoagulants also significantly reduced all-c
6               42,411 participants received a new oral anticoagulant and 29,272 participants received
7                                     Although new oral anticoagulants appear promising, clinical trial
8                                              New oral anticoagulant approval may provide safer and ea
9                                              New oral anticoagulants are a viable option for patients
10                                              New oral anticoagulants are effective for thromboprophyl
11                                 Overall, the new oral anticoagulants are poised to replace vitamin K
12 inicians a more comprehensive picture of the new oral anticoagulants as a therapeutic option to reduc
13                              Experience with new oral anticoagulants as acute, long-term, and extende
14                                         Four new oral anticoagulants compare favourably with warfarin
15                                          The new oral anticoagulants dabigatran and rivaroxaban have
16 mitations of aspirin and the availability of new oral anticoagulant drugs that overcome the inherent
17                                              New oral anticoagulants for stroke prevention in atrial
18 views the latest evidence and development of new oral anticoagulants for the prevention of ischaemic
19                                              New oral anticoagulants, for example, offer cost-effecti
20                               Development of new oral anticoagulants further simplifies acute-phase t
21                                              New oral anticoagulants had a favourable risk-benefit pr
22                                              New oral anticoagulants have not been compared with warf
23                        The potential role of new oral anticoagulants in antiphospholipid antibody syn
24   We aimed to assess the relative benefit of new oral anticoagulants in key subgroups, and the effect
25 sults from Phase II/III studies suggest that new oral anticoagulants may provide an efficacious alter
26 observed in patients with AF randomized to a new oral anticoagulant (NOAC) who transitioned to a vita
27                                              New oral anticoagulants (NOACs), including direct thromb
28                                              New oral anticoagulants (NOACs), including direct thromb
29                                          The new oral anticoagulants (NOACs), which include dabigatra
30       Data for warfarin compared against the new oral anticoagulants (OACs) in large phase III clinic
31  fibrillation who were randomised to receive new oral anticoagulants or warfarin, and trials in which
32                                     Low-dose new oral anticoagulant regimens showed similar overall r
33                                          The new oral anticoagulants should increase the number of pa
34 and effective for treating thrombosis, these new oral anticoagulants should next be studied for treat
35                                              New oral anticoagulants significantly reduced stroke or
36                                              New oral anticoagulants, statins and concomitant therapy
37 is is the first to include data for all four new oral anticoagulants studied in the pivotal phase 3 c
38                                              New oral anticoagulants (such as dabigatran, rivaroxaban
39                                              New oral anticoagulants, such as factor IIa and factor X
40 imitations that prompted the introduction of new oral anticoagulants targeting the single coagulation
41 r Xa inhibitors rivaroxaban and apixaban are new oral anticoagulants that are at least as efficacious
42               Dabigatran and rivaroxaban are new oral anticoagulants that are eliminated through the
43 ergo a major change with the introduction of new oral anticoagulants that are likely to fulfill many
44 limitations have prompted the development of new oral anticoagulants that target either factor Xa or
45           Dabigatran etexilate was the first new oral anticoagulant to be approved for long-term anti
46 Design of the Randomized Controlled Trial of New Oral Anticoagulants vs. Warfarin for post Cardiac Su
47          The relative efficacy and safety of new oral anticoagulants was consistent across a wide ran
48 er relative reduction in major bleeding with new oral anticoagulants when the centre-based time in th
49  standard'' for a dose administration of the new oral anticoagulant, where the Deltaf/DeltaGamma rati